A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Phase: PHASE2
Conditions: Mild to Moderate Alzheimer's Disease
Sponsor: Cognition Therapeutics

 
 
     Cognition Therapeutics, Inc. 
 
 
2500 Westchester Avenue Suite 220 
Purchase, NY 10577 
 
 
412-481-2210 
 
 
  
 Document: Redacted Protocol COG0201 
 
  
Official Title:  A 
Randomized, 
Double-Blind, 
Placebo-
Controlled, Parallel-Group, Phase 2 Study to Evaluate the 
Safety and Efficacy of CT1812 in Subjects With Mild to 
Moderate Alzheimer's Disease. 
  
ClinicalTrials.gov ID (NCT number): NCT03507790  
  
Protocol Date : Version 6.0_12 June 2023